- Home
- MESO vs ETY Comparison
MESO vs ETY Comparison
Compare MESO & ETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MESO | ETY |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2005 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MESO | ETY |
|---|---|---|
| Price | $16.39 | $14.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 180.2K | ★ 251.7K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $629.74 | N/A |
| Revenue Next Year | $30.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.05 | $13.12 |
| 52 Week High | $21.50 | $16.03 |
Technical Indicators
Market Signals| Indicator | MESO | ETY |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 47.71 |
| Support Level | $15.37 | $14.26 |
| Resistance Level | $17.10 | $14.79 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 1.06 | 22.53 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.